Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.
AffiliationChemokine Research Group, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
MetadataShow full item record
AbstractCancer is one of the most important pathological conditions facing mankind in the 21st century, and is likely to become the most important cause of death as improvements continue in health, diet and life expectancy. The immune response is responsible for controlling nascent cancer through immunosurveillance. If tumours escape this control, they can develop into clinical cancer. Although surgery and chemo- or radiotherapy have improved survival rates significantly, there is a drive to reharness immune responses to treat disease. As T cells are one of the key immune cells in controlling cancer, research is under way to enhance their function and improve tumour targeting. This can be achieved by transduction with tumour-specific T cell receptor (TCR) or chimaeric antigen receptors (CAR) to generate redirected T cells. Virus-specific cells can also be transduced with TCR or CAR to create bi-functional T cells with specificity for both virus and tumour. In this review we outline the development and optimization of redirected and bi-functional T cells, and outline the results from current clinical trials using these cells. From this we discuss the challenges involved in generating effective anti-tumour responses while avoiding concomitant damage to normal tissues and organs.
CitationImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. 2012, 167 (2):216-25 Clin Exp Immunol
JournalClinical and Experimental Immunology
- Engineered T cells: the promise and challenges of cancer immunotherapy.
- Authors: Fesnak AD, June CH, Levine BL
- Issue date: 2016 Aug 23
- New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.
- Authors: Schmitt TM, Stromnes IM, Chapuis AG, Greenberg PD
- Issue date: 2015 Dec 1
- Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
- Authors: Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S
- Issue date: 2013 Oct 10
- Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
- Authors: Leuci V, Mesiano G, Gammaitoni L, Aglietta M, Sangiolo D
- Issue date: 2014 Feb
- Chimeric Antigen Receptor T Cell Therapy in Hematology.
- Authors: Ataca P, Arslan Ö
- Issue date: 2015 Dec